Table IV.

Association of biomarkers with clinical outcomes, including pulmonary function (FEV1% predicted, interval change [Δ] in FEV1% predicted^∗) and growth (interval change in BMIZ/WLZ, interval change in WAZ, and BMIZ/WLZ)

Biomarkers	FEV1% predicted		ΔFEV1% predicted		ΔBMIZ/WLZ		ΔWAZ		BMIZ/WLZ
	Estimate	P value	Estimate	P value	Estimate	P value	Estimate	P value	Estimate	P value
fLcn2, μg/g	−1.253	.006	−0.2438	.5157	0.001	.967	−0.007	.480	−0.019	.442
fCal, μg/g	−0.102	.029	0.01112	.7308	−0.002	.242	−0.002	.032	−0.009	<.001
fNeo, nmol/L	−0.003	.587	0.001399	.7137	0.000	.579	0.000	.520	0.000	.809
LPS antibody, EIA units	−0.041	.628	−0.02808	.5434	0.002	.588	0.000	.796	0.001	.794
LBP, μg/g	0.253	.592	−0.1207	.6892	−0.006	.545	−0.010	.084	−0.018	.044

Interval change is considered the change over the preceding ∼3 months since last CF visit. The estimates predict the change in the clinical outcome if the biomarker increases by 1 unit and were generated using a linear mixed model with random effect accounting for within-participant correlation. Estimates with P value < .05 are bolded.

^∗As published in Cooper et al.²⁴